{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:29:47Z","timestamp":1772720987162,"version":"3.50.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To examine the real-world effectiveness and safety of peficitinib (PEF) and abatacept (ABT) in patients with rheumatoid arthritis (RA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicentre, retrospective cohort study, we examined patients who were administered PEF or ABT between July 2019 and July 2022. The primary endpoint was the 1-year retention rate of PEF or ABT. The primary analyses were performed using treatment persistence, disease activity measurements, and safety parameters. The inverse probability of treatment weighting (IPTW) was used to adjust for confounding variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 219 patients were enrolled, with 64 receiving PEF and 155 receiving ABT. The 1-year retention rates were 42.8% in the PEF group and 61.0% in the ABT group after IPTW (P\u2009=\u2009.0083). Two years following the initiation of treatment, the composite disease activity measures showed comparable improvement in both groups after IPTW. Treatment discontinuation occurred primarily because of an inadequate therapeutic response (PEF: 41.3%, ABT: 28.1%) and adverse reactions (PEF: 11.1%, ABT: 3.8%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PEF treatment resulted in lower retention rates compared with ABT, whereas both medications demonstrated effectiveness in controlling disease activity for patients who were able to continue treatment. Our findings contribute to informed decision-making in RA treatment in actual clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf094","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:09:37Z","timestamp":1760011777000},"page":"196-204","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness and safety of peficitinib and abatacept for rheumatoid arthritis: a multicentre, inverse probability weighting analysis"],"prefix":"10.1093","volume":"36","author":[{"given":"Kento","family":"Ichikawa","sequence":"first","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3915-9276","authenticated-orcid":false,"given":"Yosuke","family":"Kunishita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Clinical Immunology, Yokohama City University Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Shinoda","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Medicine, Yokohama City University , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayo","family":"Harita","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikara","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Yokohama Minami Kyosai Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Higashitani","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Iizuka","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Uzawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Yokohama Minami Kyosai Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Ohno","sequence":"additional","affiliation":[{"name":"Center for Rheumatic Diseases, Yokohama City University Medical Center , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiharu","family":"Hidekawa","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Komiya","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]},{"name":"Department of Hematology and Clinical Immunology, Yokohama City University Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuki","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Saiseikai Yokohama-Shi Nanbu Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Mitsuhashi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Yokohama Minami Kyosai Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Yokohama Minami Kyosai Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Tsuchida","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]},{"name":"Department of Hematology and Clinical Immunology, Yokohama City University Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Hirahara","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]},{"name":"Department of Hematology and Clinical Immunology, Yokohama City University Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Soejima","sequence":"additional","affiliation":[{"name":"Center for Rheumatic Diseases, Yokohama City University Medical Center , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiga","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]},{"name":"Department of Hematology and Clinical Immunology, Yokohama City University Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Yokohama Minami Kyosai Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Takase-Minegishi","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]},{"name":"Department of Hematology and Clinical Immunology, Yokohama City University Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusuke","family":"Yoshimi","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]},{"name":"Department of Hematology and Clinical Immunology, Yokohama City University Hospital , Yokohama ,","place":["Japan"]},{"name":"Clinical Laboratory Department, Yokohama City University Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Kirino","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]},{"name":"Department of Hematology and Clinical Immunology, Yokohama City University Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadanobu","family":"Okubo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Saiseikai Yokohama-Shi Nanbu Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Ohno","sequence":"additional","affiliation":[{"name":"Center for Rheumatic Diseases, Yokohama City University Medical Center , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouhei","family":"Nagaoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Yokohama Minami Kyosai Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama ,","place":["Japan"]},{"name":"Department of Hematology and Clinical Immunology, Yokohama City University Hospital , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"2026030508163937600_ref1","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"358","author":"Lee","year":"2001","journal-title":"Lancet"},{"key":"2026030508163937600_ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200422001-00002","article-title":"Epidemiology and burden of illness of rheumatoid arthritis","volume":"22","author":"Kvien","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"2026030508163937600_ref3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis - common origins, divergent mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N Engl J Med"},{"key":"2026030508163937600_ref4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","article-title":"Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026030508163937600_ref5","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"2026030508163937600_ref6","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"2026030508163937600_ref7","doi-asserted-by":"publisher","first-page":"102019","DOI":"10.1016\/j.berh.2024.102019","article-title":"Global RA treatment recommendations: an update from the various international societies","volume":"39","author":"Cubberley","year":"2025","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2026030508163937600_ref8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026030508163937600_ref9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/mr\/roac017","article-title":"Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication","volume":"33","author":"Kawahito","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026030508163937600_ref10","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026030508163937600_ref11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/1756-185X.13513","article-title":"2018 update of the APLAR recommendations for treatment of rheumatoid arthritis","volume":"22","author":"Lau","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2026030508163937600_ref12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41584-023-01036-x","article-title":"25 years of biologic DMARDs in rheumatology","volume":"19","author":"Feldmann","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2026030508163937600_ref13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","article-title":"JAK inhibitors for rheumatoid arthritis","volume":"32","author":"Kubo","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"2026030508163937600_ref14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2026030508163937600_ref15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2026030508163937600_ref16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4049\/jimmunol.1401867","article-title":"Mechanisms of Jak\/STAT signaling in immunity and disease","volume":"194","author":"Villarino","year":"2015","journal-title":"J Immunol"},{"key":"2026030508163937600_ref17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026030508163937600_ref18","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s40265-019-01131-y","article-title":"Peficitinib: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"2026030508163937600_ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.35772\/ghm.2024.01001","article-title":"Aging populations and perspectives of geriatric medicine in Japan","volume":"6","author":"Arai","year":"2024","journal-title":"Glob Health Med"},{"key":"2026030508163937600_ref20","doi-asserted-by":"publisher","first-page":"102528","DOI":"10.1016\/j.autrev.2020.102528","article-title":"Rheumatoid arthritis in the elderly: characteristics and treatment considerations","volume":"19","author":"Serhal","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2026030508163937600_ref21","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003311","article-title":"What benefit-risk trade-offs are acceptable to rheumatoid arthritis patients during treatment selection? Evidence from a multicountry choice experiment","volume":"10","author":"Alten","year":"2024","journal-title":"RMD Open"},{"key":"2026030508163937600_ref22","doi-asserted-by":"crossref","first-page":"rkac071","DOI":"10.1093\/rap\/rkac071","article-title":"Quality of life, disease activity and preferences for administration routes in rheumatoid arthritis: a multicentre, prospective, observational study","volume":"6","author":"Direskeneli","year":"2022","journal-title":"Rheumatol Adv Pract"},{"key":"2026030508163937600_ref23","doi-asserted-by":"publisher","first-page":"e0259389","DOI":"10.1371\/journal.pone.0259389","article-title":"Patient satisfaction, preferences, expectations, characteristics, and impact of suboptimal control of rheumatoid arthritis: a subgroup analysis of Japanese patients from a large international cohort study (SENSE)","volume":"16","author":"Kawahito","year":"2021","journal-title":"PLoS One"},{"key":"2026030508163937600_ref24","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/PPA.S289692","article-title":"Treatment satisfaction, patient preferences, and the impact of suboptimal disease control in a large international rheumatoid arthritis cohort: SENSE study","volume":"15","author":"Taylor","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"2026030508163937600_ref25","doi-asserted-by":"crossref","first-page":"18715","DOI":"10.1038\/s41598-020-75655-9","article-title":"Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis","volume":"10","author":"Hayashi","year":"2020","journal-title":"Sci Rep"},{"key":"2026030508163937600_ref26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1053\/j.ajkd.2021.02.338","article-title":"The association of disease activity and estimated GFR in patients with rheumatoid arthritis: findings from the ANSWER study","volume":"78","author":"Onishi","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2026030508163937600_ref27","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/S2665-9913(24)00033-X","article-title":"JAK inhibitors-friend or foe?","volume":"6","author":"The","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2026030508163937600_ref28","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2026030508163937600_ref29","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026030508163937600_ref30","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026030508163937600_ref31","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/14397595.2020.1836789","article-title":"A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years","volume":"31","author":"Takeuchi","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2026030508163937600_ref32","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/mr\/roab058","article-title":"Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2026030508163937600_ref33","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/mr\/roab069","article-title":"A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2026030508163937600_ref34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/mr\/roac021","article-title":"Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4)","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026030508163937600_ref35","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/mr\/road110","article-title":"Safety and effectiveness of peficitinib 100 mg\/day in patients achieving clinical remission from a long-term open-label extension study in Japan, Korea, and Taiwan (RAJ2)","volume":"34","author":"Tanaka","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2026030508163937600_ref36","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/mr\/road059","article-title":"Post hoc analysis of patients with rheumatoid arthritis under clinical remission in two Japanese phase 3 trials of peficitinib treatment (RAJ3 and RAJ4)","volume":"34","author":"Tanaka","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2026030508163937600_ref37","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1080\/14397595.2018.1524998","article-title":"Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance","volume":"29","author":"Harigai","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2026030508163937600_ref38","doi-asserted-by":"crossref","first-page":"1759720X231186874","DOI":"10.1177\/1759720X231186874","article-title":"Efficacy and safety of abatacept in patients with rheumatoid arthritis with previous malignancy","volume":"15","author":"Kunishita","year":"2023","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026030508163937600_ref39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2026030508163937600_ref40","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026030508163937600_ref41","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2026030508163937600_ref42","doi-asserted-by":"crossref","first-page":"292","DOI":"10.32614\/RJ-2021-073","article-title":"MatchThem:: matching and weighting after multiple imputation","volume":"13","author":"Pishgar","year":"2021","journal-title":"R J"},{"key":"2026030508163937600_ref43","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"2026030508163937600_ref44","volume-title":"R: A Language and Environment for Statistical Computing","author":"Team RC","year":"2022"},{"key":"2026030508163937600_ref45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-020-2125-2","article-title":"Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan","volume":"22","author":"Takeuchi","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2026030508163937600_ref46","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1093\/rheumatology\/kead543","article-title":"Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study","volume":"63","author":"Hayashi","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026030508163937600_ref47","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roaf043","article-title":"A retrospective chart review to explore the efficacy and safety of switching to peficitinib in Japanese patients with rheumatoid arthritis and inadequate response to biologic disease-modifying antirheumatic drugs","author":"Yamaoka","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026030508163937600_ref48","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/17425255.2024.2373092","article-title":"Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis","volume":"20","author":"Chandrashekara","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026030508163937600_ref49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","article-title":"EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis","volume":"81","author":"Nagy","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026030508163937600_ref50","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/rheumatology\/key165","article-title":"Management of inflammatory rheumatic conditions in the elderly","volume":"58","author":"Lahaye","year":"2019","journal-title":"Rheumatology (Oxford)"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf094\/64612960\/roaf094.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/2\/196\/64612960\/roaf094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/2\/196\/64612960\/roaf094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T13:16:47Z","timestamp":1772716607000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/2\/196\/8280439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,10]]},"published-print":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf094","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,10,10]]}}}